

**B. PACKAGE LEAFLET**

**PACKAGE LEAFLET:**

**1. Name of the veterinary medicinal product**

Labiprofen 150 mg/ml solution for injection for cattle, pigs and horses

**2.. Composition**

Each ml contains:

**Active substance:**

Ketoprofen 150 mg

**Excipients:**

Benzyl alcohol (E1519) 10 mg

Clear colourless to slightly yellow solution for injection, free from visible particles.

**3. Target species**

Cattle, pigs and horses

**4. Indications for use**

Cattle:

- Reduction of inflammation and pain associated with post-partum, musculoskeletal disorders and lameness.
- Reduction of fever associated with bovine respiratory disease in combination with antimicrobial therapy where appropriate.
- Reduction of inflammation, fever and pain in acute clinical mastitis in combination with antimicrobial therapy where appropriate.

Pigs:

- Reduction of pyrexia in cases of respiratory disease and Postpartum Dysgalactia Syndrome PDS (Metritis Mastitis Agalactia syndrome) in sows, in combination with antimicrobial therapy, where appropriate.

Horses:

- Reduction of inflammation and pain associated with osteoarticular and musculoskeletal disorders (lameness, laminitis, osteoarthritis, synovitis, tendinitis, etc.).
- Reduction of postoperative pain and inflammation.
- Reduction of visceral pain associated with colic.

**5. Contraindications**

Do not use in cases of gastro-intestinal ulceration or bleeding, in order not to aggravate their situation.

Do not use in cases of cardiac, hepatic, or renal disease.

January 2023

1b-spc-pl

Do not use in cases of known hypersensitivity to ketoprofen or acetyl-salicylic acid or to any of the excipients.

Do not use in cases of blood dyscrasia, coagulopathy or haemorrhagic diathesis. Do not administer other non-steroidal anti-inflammatory drugs (NSAIDs) concurrently or within 24 hours of each other.

## **6. Special warnings**

### Special precautions for safe use in the target species:

Do not exceed the recommended dose. Do not exceed the recommended treatment period.

The use of ketoprofen is not recommended in foals less than one month of age.

When administering to animals of less than 6 weeks of age, ponies or in aged animals it is necessary to adjust the dose accurately as well as to perform a close clinical follow-up. Avoid intra-arterial injection.

Avoid use in any dehydrated, hypovolaemic or hypotensive animals as there is a potential risk of increased renal toxicity.

Since gastric ulceration is a common finding in PMWS (Post-weaning Multisystemic Wasting Syndrome), the use of ketoprofen in pigs affected by this pathology is not recommended, in order not to aggravate their situation. In horses, avoid extravascular administration.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Hypersensitivity reactions (skin rash, urticaria) could occur. People with known hypersensitivity to the active substance or to any of the excipients should avoid contact with the veterinary medicinal product.

Avoid accidental self-injection. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Avoid contact with the skin, eyes and mucous membranes. In case of accidental skin, eye or mucous membrane contact, wash the affected area thoroughly with clean running water immediately. Seek medical advice if irritation persists.

Wash hands after use.

### Pregnancy and lactation:

Laboratory studies in rats, mice and rabbits, and studies in cattle have not produced any evidence of adverse effects. Can be used during pregnancy in cows.

The safety of the veterinary medicinal product has not been established during pregnancy in sows and mares. Use only according to the benefit-risk assessment by the responsible veterinarian.

Can be used during lactation in cows and sows.

The use is not recommended during lactation in mares

### Interaction with other medicinal products and other forms of interaction:

- Concurrent administration of diuretics or potentially nephrotoxic drugs should be avoided since there is an increase of renal disturbances, including renal failure. This is secondary to the diminished blood flow caused by the inhibition of prostaglandins synthesis.

- Do not administer other non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, anticoagulants or diuretics concurrently or within 24 hours of administration of the product since the risk of gastrointestinal ulceration and other adverse reactions may be exacerbated.

- The treatment free period should however take into account the pharmacological properties of the products used previously.

- Ketoprofen is highly bound to plasma proteins and may compete with other highly bound drugs which can lead to toxic effects.

January 2023

1b-spc-pl

Overdose:

Overdose with non-steroidal anti-inflammatory drugs can lead to gastro-intestinal ulceration, loss of proteins, hepatic and renal impairment.

In tolerance studies performed in pigs, up to 25% of the animals treated at three times the maximum recommended dose (9 mg/kg bw) for three days or at the recommended dose (3 mg/kg bw) for triple the maximum recommended time (9 days) showed erosive and/or ulcerative lesions in both the aglandular (pars oesophagica) and glandular parts of the stomach. Early signs of toxicity include loss of appetite and pasty faeces or diarrhoea.

The intramuscular administration of the product to cattle, at up to 3 times the recommended dose or for 3 times the recommended duration of the treatment (9 days) did not result in clinical signs of intolerance. However, inflammation as well as necrotic subclinical lesions were detected at the injection site of the treated animals as well as an increase in CPK levels. The histopathological examination showed erosive or ulcerative abomasal lesions related to both dosage regimes.

Horses have been found to tolerate intravenous dosages of ketoprofen up to 5 times the recommended dose for three times the recommended duration (15 days) with no evidence of toxic effects.

If clinical signs of overdose are observed, there is no specific antidote, therefore symptomatic treatment should be initiated.

Special restrictions for use and special conditions for use:

To be completed in accordance with national requirements after conclusion of the MRP/DCP/SRP

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

**7. Adverse events**

Cattle, pigs

Undetermined frequency (cannot be estimated from the available data)	Muscle necrosis <sup>1</sup> Erosive and ulcerative lesions of the gastrointestinal tract <sup>2</sup> Gastric or renal intolerance <sup>3</sup>
--	--

Horse

Undetermined frequency (cannot be estimated from the available data)	Muscle necrosis <sup>1</sup> Erosive and ulcerative lesions of the gastrointestinal tract <sup>2</sup> Gastric or renal intolerance <sup>3</sup> Injection site reactions <sup>4</sup>
--	---

1. After intramuscular injection, subclinical, mild and transient, gradually resolving in the days after completion of treatment. Administration in the neck region minimizes the extension and severity of these lesions.
2. After repeated administrations (due to the mechanism of action of ketoprofen).
3. In certain individuals. Due to the action of inhibition of prostaglandins' synthesis (in common with all NSAIDS).
4. Transient. Observed after one administration of the product at the recommended volume by extravascular route. Disappeared after 5 days.

If side effects occur treatment must be stopped, and the advice of a veterinarian should be sought.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system {national system details}.

## **8. Dosage for each species, routes and method of administration**

Intramuscular use: cattle, pigs  
Intravenous use: cattle, horses

### **- Cattle:**

3 mg ketoprofen/kg body weight, i.e. 1 ml of product per 50 kg body weight/ day, administered via the intravenous or intramuscular route, preferably in the neck region.

The duration of treatment is 1-3 days, and should be established according to the severity and duration of symptoms.

### **- Pigs:**

3 mg of ketoprofen/kg body weight i.e. 1 ml of the product per 50 kg body weight/ day, administered via the intramuscular route on a single occasion. Depending on the response observed and based on the benefit-risk analysis by the responsible veterinarian treatment may be repeated at intervals of 24 hours for a maximum of three treatments. Each injection should be given at a different site.

### **- Horses:**

2.2 mg of ketoprofen/kg body weight, i.e. 0.75 ml of the product. per 50 kg body weight/ day, administered via the intravenous route.

The duration of treatment is 1-5 days, and should be established according to the severity and duration of symptoms. In the case of colic one injection is normally sufficient. A second administration of ketoprofen requires a clinical re-examination.

## **9. Advice on correct administration**

January 2023

1b-spc-pl

**10. Withdrawal periods**

Cattle:

Meat and offal: 2 days

Milk: zero hours

Horses:

Meat and offal: 1 day

Milk: Not authorised for use in mares producing milk for human consumption

Pig:

Meat and offal: 3 days

**11. Special storage precautions**

Keep out of the sight and reach of children.

Keep the immediate packaging in the outer carton in order to protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and vial after Exp. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging: 28 days.

When a immediate packaging is broached (opened) for the first time, using the in-use shelf-life which is specified on this package leaflet, the date on which any product remaining in the immediate packaging should be discarded should be worked out. This discard date should be written in the space provided.

**12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or &lt;household waste&gt;

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

**13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription

**14. Marketing authorisation numbers and pack sizes**

MA numbers: XXXXX

Package sizes:

Box containing 1 vial of 50 ml

Box containing 1 vial of 100 ml

Box containing 1 vial of 250 ml

January 2023

1b-spc-pl

Box containing 12 vials of 50 ml  
Box containing 10 vials of 100 ml  
Box containing 10 vials of 250 ml

Not all pack sizes may be marketed.

**15. Date on which the package leaflet was last revised**

{MM/YYYY}

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

**16. Contact details**

Marketing authorisation holder and manufacturer responsible for batch release and contact details to report suspected adverse reactions:

Labiana Life Sciences S.A. - Venus 26 - 08228 Terrassa (Barcelona) - Spain.

Local representative and contact details to report suspected adverse reactions:

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

**17. Other information**